個別化がん医療の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE2691)
◆英語タイトル:Global Personalized Cancer Medicine Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE2691
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:109
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、個別化がん医療の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(モノクローナル抗体、個別化がんワクチン、その他)、用途別市場規模(乳がん、肺がん、慢性骨髄性白血病、大腸がん、その他のがん)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・個別化がん医療の市場動向
・企業の競争状況、市場シェア
・個別化がん医療の種類別市場規模(モノクローナル抗体、個別化がんワクチン、その他)
・個別化がん医療の用途別市場規模(乳がん、肺がん、慢性骨髄性白血病、大腸がん、その他のがん)
・個別化がん医療の北米市場規模2016-2027(アメリカ、カナダ)
・個別化がん医療の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・個別化がん医療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・個別化がん医療の中南米市場規模2016-2027(メキシコ、ブラジル)
・個別化がん医療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Abbott、Merck、Novartis、Amgen、Celgene、Bayer、Roche、Astellas、Astrazeneca、Johnson & Johnson、Agilent、Takeda)
・結論
【レポートの概要】

Personalized medicine is at an early stage of development. Scientists found that some cancer cells have particular proteins in the cell and others don’t. Sometimes, cancer cells have far more of a particular protein than healthy cells. Genetic testing of cancer cells and normal cells helps doctors customize treatment to individual patient needs. Personalized treatments may cause fewer side effects than standard options. Some people are already benefiting from this approach.

Market Analysis and Insights: Global Personalized Cancer Medicine Market
The global Personalized Cancer Medicine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Personalized Cancer Medicine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Personalized Cancer Medicine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Personalized Cancer Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Personalized Cancer Medicine market.

Global Personalized Cancer Medicine Scope and Market Size
Personalized Cancer Medicine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Personalized Cancer Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monoclonal Antibodies
Personalized Cancer Vaccines
Other

Segment by Application
Breast Cancer
Lung Cancer
Chronic Myeloid Leukaemia
Bowel Cancer
Other Cancer

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott
Merck
Novartis
Amgen
Celgene
Bayer
Roche
Astellas
Astrazeneca
Johnson & Johnson
Agilent
Takeda

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Cancer Medicine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Monoclonal Antibodies
1.2.3 Personalized Cancer Vaccines
1.2.4 Other
1.3 Market by Application
1.3.1 Global Personalized Cancer Medicine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Chronic Myeloid Leukaemia
1.3.5 Bowel Cancer
1.3.6 Other Cancer
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Personalized Cancer Medicine Market Perspective (2016-2027)
2.2 Personalized Cancer Medicine Growth Trends by Regions
2.2.1 Personalized Cancer Medicine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Personalized Cancer Medicine Historic Market Share by Regions (2016-2021)
2.2.3 Personalized Cancer Medicine Forecasted Market Size by Regions (2022-2027)
2.3 Personalized Cancer Medicine Industry Dynamic
2.3.1 Personalized Cancer Medicine Market Trends
2.3.2 Personalized Cancer Medicine Market Drivers
2.3.3 Personalized Cancer Medicine Market Challenges
2.3.4 Personalized Cancer Medicine Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Personalized Cancer Medicine Players by Revenue
3.1.1 Global Top Personalized Cancer Medicine Players by Revenue (2016-2021)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2016-2021)
3.2 Global Personalized Cancer Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Personalized Cancer Medicine Revenue
3.4 Global Personalized Cancer Medicine Market Concentration Ratio
3.4.1 Global Personalized Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Cancer Medicine Revenue in 2020
3.5 Personalized Cancer Medicine Key Players Head office and Area Served
3.6 Key Players Personalized Cancer Medicine Product Solution and Service
3.7 Date of Enter into Personalized Cancer Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Personalized Cancer Medicine Breakdown Data by Type
4.1 Global Personalized Cancer Medicine Historic Market Size by Type (2016-2021)
4.2 Global Personalized Cancer Medicine Forecasted Market Size by Type (2022-2027)

5 Personalized Cancer Medicine Breakdown Data by Application
5.1 Global Personalized Cancer Medicine Historic Market Size by Application (2016-2021)
5.2 Global Personalized Cancer Medicine Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Personalized Cancer Medicine Market Size (2016-2027)
6.2 North America Personalized Cancer Medicine Market Size by Type
6.2.1 North America Personalized Cancer Medicine Market Size by Type (2016-2021)
6.2.2 North America Personalized Cancer Medicine Market Size by Type (2022-2027)
6.2.3 North America Personalized Cancer Medicine Market Size by Type (2016-2027)
6.3 North America Personalized Cancer Medicine Market Size by Application
6.3.1 North America Personalized Cancer Medicine Market Size by Application (2016-2021)
6.3.2 North America Personalized Cancer Medicine Market Size by Application (2022-2027)
6.3.3 North America Personalized Cancer Medicine Market Size by Application (2016-2027)
6.4 North America Personalized Cancer Medicine Market Size by Country
6.4.1 North America Personalized Cancer Medicine Market Size by Country (2016-2021)
6.4.2 North America Personalized Cancer Medicine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Personalized Cancer Medicine Market Size (2016-2027)
7.2 Europe Personalized Cancer Medicine Market Size by Type
7.2.1 Europe Personalized Cancer Medicine Market Size by Type (2016-2021)
7.2.2 Europe Personalized Cancer Medicine Market Size by Type (2022-2027)
7.2.3 Europe Personalized Cancer Medicine Market Size by Type (2016-2027)
7.3 Europe Personalized Cancer Medicine Market Size by Application
7.3.1 Europe Personalized Cancer Medicine Market Size by Application (2016-2021)
7.3.2 Europe Personalized Cancer Medicine Market Size by Application (2022-2027)
7.3.3 Europe Personalized Cancer Medicine Market Size by Application (2016-2027)
7.4 Europe Personalized Cancer Medicine Market Size by Country
7.4.1 Europe Personalized Cancer Medicine Market Size by Country (2016-2021)
7.4.2 Europe Personalized Cancer Medicine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Personalized Cancer Medicine Market Size (2016-2027)
8.2 Asia-Pacific Personalized Cancer Medicine Market Size by Type
8.2.1 Asia-Pacific Personalized Cancer Medicine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Personalized Cancer Medicine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Personalized Cancer Medicine Market Size by Type (2016-2027)
8.3 Asia-Pacific Personalized Cancer Medicine Market Size by Application
8.3.1 Asia-Pacific Personalized Cancer Medicine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Personalized Cancer Medicine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Personalized Cancer Medicine Market Size by Application (2016-2027)
8.4 Asia-Pacific Personalized Cancer Medicine Market Size by Region
8.4.1 Asia-Pacific Personalized Cancer Medicine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Personalized Cancer Medicine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Personalized Cancer Medicine Market Size (2016-2027)
9.2 Latin America Personalized Cancer Medicine Market Size by Type
9.2.1 Latin America Personalized Cancer Medicine Market Size by Type (2016-2021)
9.2.2 Latin America Personalized Cancer Medicine Market Size by Type (2022-2027)
9.2.3 Latin America Personalized Cancer Medicine Market Size by Type (2016-2027)
9.3 Latin America Personalized Cancer Medicine Market Size by Application
9.3.1 Latin America Personalized Cancer Medicine Market Size by Application (2016-2021)
9.3.2 Latin America Personalized Cancer Medicine Market Size by Application (2022-2027)
9.3.3 Latin America Personalized Cancer Medicine Market Size by Application (2016-2027)
9.4 Latin America Personalized Cancer Medicine Market Size by Country
9.4.1 Latin America Personalized Cancer Medicine Market Size by Country (2016-2021)
9.4.2 Latin America Personalized Cancer Medicine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Personalized Cancer Medicine Market Size (2016-2027)
10.2 Middle East & Africa Personalized Cancer Medicine Market Size by Type
10.2.1 Middle East & Africa Personalized Cancer Medicine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Personalized Cancer Medicine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Personalized Cancer Medicine Market Size by Type (2016-2027)
10.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application
10.3.1 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2016-2027)
10.4 Middle East & Africa Personalized Cancer Medicine Market Size by Country
10.4.1 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Personalized Cancer Medicine Introduction
11.1.4 Abbott Revenue in Personalized Cancer Medicine Business (2016-2021)
11.1.5 Abbott Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Personalized Cancer Medicine Introduction
11.2.4 Merck Revenue in Personalized Cancer Medicine Business (2016-2021)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Personalized Cancer Medicine Introduction
11.3.4 Novartis Revenue in Personalized Cancer Medicine Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Personalized Cancer Medicine Introduction
11.4.4 Amgen Revenue in Personalized Cancer Medicine Business (2016-2021)
11.4.5 Amgen Recent Development
11.5 Celgene
11.5.1 Celgene Company Details
11.5.2 Celgene Business Overview
11.5.3 Celgene Personalized Cancer Medicine Introduction
11.5.4 Celgene Revenue in Personalized Cancer Medicine Business (2016-2021)
11.5.5 Celgene Recent Development
11.6 Bayer
11.6.1 Bayer Company Details
11.6.2 Bayer Business Overview
11.6.3 Bayer Personalized Cancer Medicine Introduction
11.6.4 Bayer Revenue in Personalized Cancer Medicine Business (2016-2021)
11.6.5 Bayer Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Personalized Cancer Medicine Introduction
11.7.4 Roche Revenue in Personalized Cancer Medicine Business (2016-2021)
11.7.5 Roche Recent Development
11.8 Astellas
11.8.1 Astellas Company Details
11.8.2 Astellas Business Overview
11.8.3 Astellas Personalized Cancer Medicine Introduction
11.8.4 Astellas Revenue in Personalized Cancer Medicine Business (2016-2021)
11.8.5 Astellas Recent Development
11.9 Astrazeneca
11.9.1 Astrazeneca Company Details
11.9.2 Astrazeneca Business Overview
11.9.3 Astrazeneca Personalized Cancer Medicine Introduction
11.9.4 Astrazeneca Revenue in Personalized Cancer Medicine Business (2016-2021)
11.9.5 Astrazeneca Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Details
11.10.2 Johnson & Johnson Business Overview
11.10.3 Johnson & Johnson Personalized Cancer Medicine Introduction
11.10.4 Johnson & Johnson Revenue in Personalized Cancer Medicine Business (2016-2021)
11.10.5 Johnson & Johnson Recent Development
11.11 Agilent
11.11.1 Agilent Company Details
11.11.2 Agilent Business Overview
11.11.3 Agilent Personalized Cancer Medicine Introduction
11.11.4 Agilent Revenue in Personalized Cancer Medicine Business (2016-2021)
11.11.5 Agilent Recent Development
11.12 Takeda
11.12.1 Takeda Company Details
11.12.2 Takeda Business Overview
11.12.3 Takeda Personalized Cancer Medicine Introduction
11.12.4 Takeda Revenue in Personalized Cancer Medicine Business (2016-2021)
11.12.5 Takeda Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 個別化がん医療の世界市場規模・現状・予測2021年-2027年(Global Personalized Cancer Medicine Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。